ASRS 2024

Jul 17 - Jul 20, 2024 | Stockholm, Sweden

Share this page

Close Tooltip
Copy Link Tooltip

Copy page URL

Four-Year Outcomes of Faricimab▼ in DME: First Time Safety and Efficacy Results From the RHONE-X Long-Term Extension Trial

Authors Khanani A, Kotecha A, Harrell E, Abreu F, Tang Y, Willis J, Sim D

Published date17 July, 2024

This presentation reports, for the first time, findings from the RHONE-X extension trial, which evaluated the long-term safety and efficacy of faricimab▼ in patients with DME. Findings show that faricimab▼ was well tolerated with a safety profile that was consistent with the YOSEMITE/RHINE parent trials, while efficacy and durability achieved with faricimab▼ during the parent trials were maintained for an additional 2 years in this long-term extension trial.

Download Current View

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.